Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
24 versus 48 weeks of Pegasys + Copegus in chronic hepatitis C genotype 2 or 3 without rapid viral response
2007-004993-15Phase 3Completed
- Sponsor
- Roche
- Start
- Feb 2008
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by Roche. Primary endpoints: Sustained virological response at 24 weeks after treatment completion and Clearance of HCV viremia at 72 weeks after treatment initiation. Started Feb 2008; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2007-004993-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004993-15.